Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 93.13% is 10% above its 5-year average of 84.48%, near the high end of its 5-year range (44.80%–100.54%).
18.75% above its 12-month average of 78.42%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 52.55%.
GROSS MARGIN
93.13%
GROSS MARGIN AVG TTM
78.42%
GROSS MARGIN AVG 3Y
93.39%
GROSS MARGIN AVG 5Y
84.48%
GROSS MARGIN AVG 10Y
66.65%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+18.75%
CURRENT VS 3Y AVG
-0.27%
CURRENT VS 5Y AVG
+10.25%
CURRENT VS 10Y AVG
+39.72%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.69%
median of 507 covered companies
CURRENT VS SECTOR MEDIAN
+99.46%
vs the sector median at left
BioStem Technologies, Inc.
Market Cap
$46.88M
Gross Margin
93.13%
TTM Avg
78.42%
3Y Avg
93.39%
5Y Avg
84.48%
Market Cap
$47.64M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
65.99%
Market Cap
$45.68M
Gross Margin
0.00%
TTM Avg
1.89%
3Y Avg
44.91%
5Y Avg
29.94%
Market Cap
$42.41M
Gross Margin
56.09%
TTM Avg
52.85%
3Y Avg
42.50%
5Y Avg
40.42%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | $46.88M | 93.13% | 78.42% | 93.39% | 84.48% |
| Lite Strategy, Inc. (LITS)vs › | $47.64M | 0.00% | 0.00% | 50.00% | 65.99% |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.68M | 0.00% | 1.89% | 44.91% | 29.94% |
| Celularity Inc. (CELU)vs › | $49.21M | 79.62% | 74.20% | 42.17% | 48.15% |
| biote Corp. (BTMD)vs › | $49.40M | 71.46% | 70.99% | 69.42% | 67.35% |
| Clene Inc. (CLNN)vs › | $49.84M | 78.50% | 79.02% | 83.51% | 77.08% |
| Apollomics, Inc. (APLM)vs › | $51.17M | 97.00% | 98.50% | 99.25% | 99.50% |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | 0.00% | 0.00% | 0.00% | 0.00% |
| DarioHealth Corp. (DRIO)vs › | $42.41M | 56.09% | 52.85% | 42.50% | 40.42% |
| INmune Bio, Inc. (INMB)vs › | $51.84M | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
93.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 52.55% |
| 2026-03-31 | 52.47% |
| 2025-12-31 | 100.54% |
| 2025-09-30 | 87.95% |
| 2025-06-30 | 98.61% |
| 2025-03-31 | 98.82% |
| 2024-12-31 | 96.56% |
| 2024-09-30 | 94.87% |
| 2024-06-30 | 94.90% |
| 2024-03-31 | 94.57% |
| 2023-12-31 | 93.88% |
| 2023-09-30 | 91.46% |
| 2023-06-30 | 75.09% |
| 2023-03-31 | 82.44% |
| 2022-12-31 | 84.24% |
| 2022-09-30 | 79.23% |
| 2022-06-30 | 86.17% |
| 2022-03-31 | 90.07% |
| 2021-12-31 | 76.16% |
| 2021-09-30 | 58.92% |
| 2021-06-30 | 44.80% |
| 2021-03-31 | 77.28% |
| 2020-12-31 | 63.25% |
| 2020-09-30 | 44.96% |
| 2020-06-30 | 13.18% |
| 2020-03-31 | 45.51% |
| 2019-12-31 | 78.70% |
| 2019-09-30 | 40.11% |
| 2019-06-30 | 33.88% |
| 2019-03-31 | 48.13% |
| 2018-12-31 | -0.54% |
| 2018-09-30 | 63.95% |
| 2018-06-30 | 43.63% |
| 2018-03-31 | 59.16% |
| 2017-12-31 | 33.52% |
| 2017-09-30 | 67.20% |
| 2017-06-30 | 69.16% |
| 2017-03-31 | 57.57% |
| 2016-12-31 | 49.70% |
| 2016-09-30 | 49.12% |
| 2016-06-30 | 60.99% |
| 2016-03-31 | 77.31% |
| 2015-12-31 | 55.82% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 100.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 100.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
